AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01243762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
Study NCT01243762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
Study NCT01243762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
Study NCT01243762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
Study NCT03133429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MER
Description: carotid artery stenting
Study NCT01642472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate - open label
Description: Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
Study NCT00998166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour
Study NCT00998166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 4. Cisplatin 75mg/m2 IV over 60-120 minutes
Study NCT00998166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5. Bevacizumab 15mg/kg IV over 90 minutes
Study NCT02305199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
Study NCT02305199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Fluid containing Sodium chloride 9 g/L
Study NCT00396357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT00396357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT04537312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Nipple Sparing Mastectomy
Description: Under RNSM
Study NCT04537312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: ancillary correlative
Study NCT04537312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNSM
Description: Robot-assisted Nipple Sparing Mastectomy
Study NCT03454191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
Study NCT03454191 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No injection
Description: No injection
Study NCT00475657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study NCT00475657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study NCT03612869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS-SAF302
Description: Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
Study NCT03276858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN00808
Description: Investigational drug
Study NCT03276858 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CRN00808
Description: Investigational drug
Study NCT03276858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo
Study NCT03276858 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam oral solution
Description: Midazolam as part of the drug-drug interaction arm of the study
Study NCT03276858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT04505592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
Study NCT04505592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
Study NCT05188768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT05188768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT05188768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT05188768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT02883400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 25 mg up to 50 mg
Study NCT04284046 — intervention group
Intervention type: OTHER
Intervention: CT score
Description: CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
Study NCT00413322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: 300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
Study NCT00413322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
Study NCT03796572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
Study NCT03796572 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Puncture Wound and Dressing
Description: No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
Study NCT01521975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine, Adefovir dipivoxil
Description: All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
Study NCT03560765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED
Description: Training in the use of mainstream electronic devices with accessibility options
Study NCT03560765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MED
Description: Training in the use of mainstream electronic devices with accessibility options
Study NCT03560765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buddy
Description: A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
Study NCT03560765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buddy
Description: A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
Study NCT03557073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative phone call
Description: The intervention is a phone call on the day following surgery.
Study NCT03710824 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: diagnosed IPF patients initiating treatment with nintedanib
Study NCT01405989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral
Study NCT01405989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: oral
Study NCT03628573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (MagPro X100).
Description: accelerated rTMS.
Study NCT03628573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Theta burst stimulation ( iTBS)
Study NCT03829995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug counseling
Description: Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
Study NCT01260064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open appendectomy
Description: The subjects will have traditional open appendectomy procedure.
Study NCT01260064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy with metal endoclips
Description: The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
Study NCT01260064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy with suture ligation
Description: The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
Study NCT04585828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon
Description: The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
Study NCT04585828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm
Description: The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
Study NCT02095834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT02095834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT02095834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02095834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00207116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
Study NCT03045107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)
Description: After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
Study NCT03045107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)
Description: After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
Study NCT04359758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Streamlined Genetic Education and Testing
Description: This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
Study NCT04359758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
Study NCT01135251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimiracetam
Description: 400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
Study NCT01135251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
Study NCT01429142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
Study NCT01429142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS intervention
Description: The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo.
Study NCT00953576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Study NCT00953576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Study NCT03103087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study NCT01576354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged-release Fampridine
Description: 10mg tablet twice a day (every 12 hours), orally
Study NCT01576354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
Study NCT02105987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC FDC
Description: Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
Study NCT03326700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
Study NCT01949090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
Study NCT01949090 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
Study NCT00122408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergyphilus
Description: 5 pills a day of Ergyphilus or placebo
Study NCT00122408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergyphilus
Description: 5 pills a day of Ergyphilus or placebo
Study NCT03760523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
Study NCT03988764 — intervention group
Intervention type: OTHER
Intervention: None AHT
Description: No further intervention planned for either group as part of the current study.
Study NCT01574352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small intervention
Description: The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
Study NCT01574352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention camp
Description: The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
Study NCT04642729 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh Corneal Lenticule Implantation using Relex-Smile Surgery
Description: Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
Study NCT01532765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy and epiretinal membrane peel
Description: 23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
Study NCT00953576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Study NCT00953576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Study NCT03957291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
Study NCT03957291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
Study NCT01532765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peel assisted by ICG
Description: Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
Study NCT01532765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CE-IOL
Description: Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant